Factor VIII (FVIII) assays for hemophilia A diagnosis, monitoring, and inhibitor detection.
Aniara offers one-stage clotting and chromogenic FVIII activity assays — including configurations suited to emicizumab-treated samples — plus FVIII antigen and anti-FVIII inhibitor (ZYMUTEST™ / Bethesda) testing. Emicizumab is a therapeutic agent referenced as an interferent, not an Aniara product. Results are interpreted by qualified laboratories; regulatory status varies.
Download Factor VIII flyers below.
Handouts / Videos
H-033-00
BIOPHEN FVIII Flyer (including Emicizumab-Insensitive Variant)
[NEW]
H-007-00
Optimized Assays for FVIII and FIX Handout
Products
- BIOPHEN FVIII:C (A221402-CAN / A221402-RUO, A221406-CAN / A221406-RUO)
- BIOPHEN FVIII Variant (A227102-RUO)
- FVIII:C Deficient Plasma (ADP040K-CAN / ADP040K-RUO)
Categories